<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36342754</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>146</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>02</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Promoting regeneration while blocking cell death preserves motor neuron function in a model of ALS.</ArticleTitle><Pagination><StartPage>2016</StartPage><EndPage>2028</EndPage><MedlinePgn>2016-2028</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awac415</ELocationID><Abstract><AbstractText>Amyotrophic lateral sclerosis (ALS) is a devastating and fatal neurodegenerative disease of motor neurons with very few treatment options. We had previously found that motor neuron degeneration in a mouse model of ALS can be delayed by deleting the axon damage sensor MAP3K12 or dual leucine zipper kinase (DLK). However, DLK is also involved in axon regeneration, prompting us to ask whether combining DLK deletion with a way to promote axon regeneration would result in greater motor neuron protection. To achieve this, we used a mouse line that constitutively expresses ATF3, a master regulator of regeneration in neurons. Although there is precedence for each individual strategy in the SOD1G93A mouse model of ALS, these have not previously been combined. By several lines of evidence including motor neuron electrophysiology, histology and behaviour, we observed a powerful synergy when combining DLK deletion with ATF3 expression. The combinatorial strategy resulted in significant protection of motor neurons with fewer undergoing cell death, reduced axon degeneration and preservation of motor function and connectivity to muscle. This study provides a demonstration of the power of combinatorial therapy to treat neurodegenerative disease.</AbstractText><CopyrightInformation>Published by Oxford University Press on behalf of the Guarantors of Brain 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wlaschin</LastName><ForeName>Josette J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Eunice Kennedy Shriver National Institute for Child Health and Human Development, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biology, Johns Hopkins University, Baltimore, MD 21218, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Donahue</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Eunice Kennedy Shriver National Institute for Child Health and Human Development, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gluski</LastName><ForeName>Jacob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Eunice Kennedy Shriver National Institute for Child Health and Human Development, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osborne</LastName><ForeName>Jennifer F</ForeName><Initials>JF</Initials><AffiliationInfo><Affiliation>Eunice Kennedy Shriver National Institute for Child Health and Human Development, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos</LastName><ForeName>Leana M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Eunice Kennedy Shriver National Institute for Child Health and Human Development, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silberberg</LastName><ForeName>Hanna</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Eunice Kennedy Shriver National Institute for Child Health and Human Development, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Le Pichon</LastName><ForeName>Claire E</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0000-0002-9274-3615</Identifier><AffiliationInfo><Affiliation>Eunice Kennedy Shriver National Institute for Child Health and Human Development, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA HD008966</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D013482">Superoxide Dismutase</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013482" MajorTopicYN="N">Superoxide Dismutase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009416" MajorTopicYN="N">Nerve Regeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009046" MajorTopicYN="N">Motor Neurons</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016923" MajorTopicYN="N">Cell Death</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">SOD1</Keyword><Keyword MajorTopicYN="N">axon regeneration</Keyword><Keyword MajorTopicYN="N">combinatorial therapy</Keyword><Keyword MajorTopicYN="N">motor neuron</Keyword><Keyword MajorTopicYN="N">neuronal death</Keyword></KeywordList><CoiStatement>The authors report no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>7</Day><Hour>11</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36342754</ArticleId><ArticleId IdType="pmc">PMC10411937</ArticleId><ArticleId IdType="doi">10.1093/brain/awac415</ArticleId><ArticleId IdType="pii">6808981</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mehta P, Kaye W, Raymond J, et al. . Prevalence of amyotrophic lateral sclerosis&#x2014;United States, 2015. Morbidity Mortal Wkly Rep. 2018;67:1285&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6289079</ArticleId><ArticleId IdType="pubmed">30462626</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen JJ. Overview of current and emerging therapies for amyotrophic lateral sclerosis. Am J Managed Care. 2020;26(Suppl 9):S191&#x2013;S197.</Citation><ArticleIdList><ArticleId IdType="pubmed">32840332</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman L, Cudkowicz M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:481&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">21511200</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Talbot K, et al. . Improving clinical trial outcomes in amyotrophic lateral sclerosis. Nat Rev Neurol. 2021;17:104&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7747476</ArticleId><ArticleId IdType="pubmed">33340024</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, et al. . Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurney ME, Pu H, Chiu AY, et al. . Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science. 1994;264:1772&#x2013;1775.</Citation><ArticleIdList><ArticleId IdType="pubmed">8209258</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Pichon CE, Meilandt WJ, Dominguez S, et al. . Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease. Sci Transl Med. 2017;9:eaag0394.</Citation><ArticleIdList><ArticleId IdType="pubmed">28814543</ArticleId></ArticleIdList></Reference><Reference><Citation>Sengupta Ghosh A, Wang B, Pozniak CD, Chen M, Watts RJ, Lewcock JW. DLK induces developmental neuronal degeneration via selective regulation of proapoptotic JNK activity. J Cell Biol. 2011;194:751&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3171129</ArticleId><ArticleId IdType="pubmed">21893599</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirai S-I, Cui DF, Miyata T, et al. . The c-Jun N-terminal kinase activator dual leucine zipper kinase regulates axon growth and neuronal migration in the developing cerebral cortex. J Neurosci. 2006;26:11992&#x2013;12002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674859</ArticleId><ArticleId IdType="pubmed">17108173</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Ritchie EM, Steinke CL, et al. . Activation of MAP3K DLK and LZK in Purkinje cells causes rapid and slow degeneration depending on signaling strength. Elife. 2021;10:e63509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7870138</ArticleId><ArticleId IdType="pubmed">33475086</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkins TA, Wang B, Huntwork-Rodriguez S, et al. . DLK Initiates a transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc Natl Acad Sci USA. 2013;110:4039&#x2013;4044.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3593899</ArticleId><ArticleId IdType="pubmed">23431164</ArticleId></ArticleIdList></Reference><Reference><Citation>Asghari Adib E, Smithson LJ, Collins CA. An axonal stress response pathway: Degenerative and regenerative signaling by DLK. Curr Opin Neurobiol. 2018;53:110&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536440</ArticleId><ArticleId IdType="pubmed">30053694</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan D, Wu Z, Chisholm AD, Jin Y. The DLK-1 kinase promotes mRNA stability and local translation in C. elegans synapses and axon regeneration. Cell. 2009;138:1005&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2772821</ArticleId><ArticleId IdType="pubmed">19737525</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammarlund M, Nix P, Hauth L, Jorgensen EM, Bastiani M. Axon regeneration requires a conserved MAP kinase pathway. Science. 2009;323:802&#x2013;806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2729122</ArticleId><ArticleId IdType="pubmed">19164707</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, Wang Z, Ghosh-Roy A, et al. . Axon regeneration pathways identified by systematic genetic screening in C. elegans. Neuron. 2011;71:1043&#x2013;1057.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3183436</ArticleId><ArticleId IdType="pubmed">21943602</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong X, Wang X, Ewanek R, Bhat P, DiAntonio A, Collins CA. Protein turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal injury. J Cell Biol. 2010;191:211&#x2013;223.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953441</ArticleId><ArticleId IdType="pubmed">20921142</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Cho Y, Beirowski B, Milbrandt J, Cavalli V, DiAntonio A. Dual leucine zipper kinase is required for retrograde injury signaling and axonal regeneration. Neuron. 2012;74:1015&#x2013;1022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3383631</ArticleId><ArticleId IdType="pubmed">22726832</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin JE, Ha H, Kim YK, Cho Y, DiAntonio A. DLK regulates a distinctive transcriptional regeneration program after peripheral nerve injury. Neurobiol Dis. 2019;127:178&#x2013;192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6588443</ArticleId><ArticleId IdType="pubmed">30735704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wlaschin JJ, Gluski JM, Nguyen E, et al. . Dual leucine zipper kinase is required for mechanical allodynia and microgliosis after nerve injury. Elife. 2018;7:e33910.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6029846</ArticleId><ArticleId IdType="pubmed">29968565</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Z, Deng N, Liu K, Zeng W. DLK mediates the neuronal intrinsic immune response and regulates glial reaction and neuropathic pain. Exp Neurol. 2019;322:113056.</Citation><ArticleIdList><ArticleId IdType="pubmed">31494101</ArticleId></ArticleIdList></Reference><Reference><Citation>Renthal W, Tochitsky I, Yang L, et al. . Transcriptional reprogramming of distinct peripheral sensory neuron subtypes after axonal injury. Neuron. 2020;108:128&#x2013;144.e9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590250</ArticleId><ArticleId IdType="pubmed">32810432</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen MQ, Le Pichon CE, Ryba N. Stereotyped transcriptomic transformation of somatosensory neurons in response to injury. Elife. 2019;8:e49679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6783272</ArticleId><ArticleId IdType="pubmed">31592768</ArticleId></ArticleIdList></Reference><Reference><Citation>Gey M, Wanner R, Schilling C, Pedro MT, Sinske D, Kn&#xf6;ll B. Atf3 mutant mice show reduced axon regeneration and impaired regeneration-associated gene induction after peripheral nerve injury. Open Biol. 2016;6:160091.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5008009</ArticleId><ArticleId IdType="pubmed">27581653</ArticleId></ArticleIdList></Reference><Reference><Citation>Seijffers R, Allchorne AJ, Woolf CJ. The transcription factor ATF-3 promotes neurite outgrowth. Mol Cell Neurosci. 2006;32(1-2):143&#x2013;154.</Citation><ArticleIdList><ArticleId IdType="pubmed">16713293</ArticleId></ArticleIdList></Reference><Reference><Citation>Seijffers R, Zhang J, Matthews JC, et al. . ATF3 expression improves motor function in the ALS mouse model by promoting motor neuron survival and retaining muscle innervation. Proc Natl Acad Sci USA. 2014;111:1622&#x2013;1627.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3910594</ArticleId><ArticleId IdType="pubmed">24474789</ArticleId></ArticleIdList></Reference><Reference><Citation>Pozniak CD, Ghosh AS, Gogineni A, et al. . Dual leucine zipper kinase is required for excitotoxicity-induced neuronal degeneration. J Exp Med. 2013;210:2553&#x2013;2567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3832926</ArticleId><ArticleId IdType="pubmed">24166713</ArticleId></ArticleIdList></Reference><Reference><Citation>Seijffers R, Mills CD, Woolf CJ. ATF3 increases the intrinsic growth state of DRG neurons to enhance peripheral nerve regeneration. J Neurosci. 2007;27:7911&#x2013;7920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672733</ArticleId><ArticleId IdType="pubmed">17652582</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatzipetros T, Kidd JD, Moreno AJ, Thompson K, Gill A, Vieira FG. A quick phenotypic neurological scoring system for evaluating disease progression in the SOD1-G93A mouse model of ALS. J Vis Exp. 2015;104:53257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4692639</ArticleId><ArticleId IdType="pubmed">26485052</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanning KC, Kaplan A, Henderson CE. Motor neuron diversity in development and disease. Annu Rev Neurosci. 2010;33:409&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">20367447</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey D, Schneider C, Xu L, Borg J, Spooren W, Caroni P. Early and selective loss of neuromuscular synapse subtypes with low sprouting competence in motoneuron diseases. J Neurosci. 2000;20:2534&#x2013;2542.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772256</ArticleId><ArticleId IdType="pubmed">10729333</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun S, Santos AF, Saxena S, Xu L, Caroni P. Selective vulnerability and pruning of phasic motoneuron axons in motoneuron disease alleviated by CNTF. Nat Neurosci. 2006;9:408&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">16474388</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J, Putman CT, Tyreman N, Gordon T. Preferential motor unit loss in the SOD1G93A transgenic mouse model of amyotrophic lateral sclerosis. J Physiol. 2008;586:3337&#x2013;3351.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2538809</ArticleId><ArticleId IdType="pubmed">18467368</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlug AS, Teuling E, Haasdijk ED, French P, Hoogenraad CC, Jaarsma D. ATF3 expression precedes death of spinal motoneurons in amyotrophic lateral sclerosis-SOD1 transgenic mice and correlates with c-Jun phosphorylation, CHOP expression, somato-dendritic ubiquitination and Golgi fragmentation. Eur J Neurosci. 2005;22:1881&#x2013;1894.</Citation><ArticleIdList><ArticleId IdType="pubmed">16262628</ArticleId></ArticleIdList></Reference><Reference><Citation>Wier CG, Crum AE, Reynolds AB, et al. . Muscle contractility dysfunction precedes loss of motor unit connectivity in SOD1(G93A) mice. Muscle Nerve. 2019;59:254&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340745</ArticleId><ArticleId IdType="pubmed">30370671</ArticleId></ArticleIdList></Reference><Reference><Citation>Hegedus J, Putman CT, Gordon T. Time course of preferential motor unit loss in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Neurobiol Dis. 2007;28:154&#x2013;164.</Citation><ArticleIdList><ArticleId IdType="pubmed">17766128</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng G, Mellor RH, Bernstein Met al. . Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 2000;28:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">11086982</ArticleId></ArticleIdList></Reference><Reference><Citation>Prell T, Gaur N, Stubendorff B, R&#xf6;diger A, Witte OW, Grosskreutz J. Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis. J Neurol Sci. 2019;397:92&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">30597420</ArticleId></ArticleIdList></Reference><Reference><Citation>Simmons Z. Patient-perceived outcomes and quality of life in ALS. Neurotherapeutics. 2015;12:394&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4404446</ArticleId><ArticleId IdType="pubmed">25502407</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein L, Atkins L, Leigh P. Correlates of quality of life in people with motor neuron disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:123&#x2013;129.</Citation><ArticleIdList><ArticleId IdType="pubmed">12495573</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L, Oudart H, Ren&#xe9; F, de Aguilar JLG, Loeffler JP. Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: Benefit of a high-energy diet in a transgenic mouse model. Proc Natl Acad Sci USA. 2004;101:11159&#x2013;11164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC503756</ArticleId><ArticleId IdType="pubmed">15263088</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbuzova-Davis S, Haller E, Saporta S, Kolomey I, Nicosia SV, Sanberg PR. Ultrastructure of blood&#x2013;brain barrier and blood&#x2013;spinal cord barrier in SOD1 mice modeling ALS. Brain Res. 2007;1157:126&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512910</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee R, Mosley RL, Reynolds AD, et al. . Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One. 2008;3:e2740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2481277</ArticleId><ArticleId IdType="pubmed">18648532</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Kindy MS, Kruman I, Mattson MP. ALS-linked Cu/Zn-SOD mutation impairs cerebral synaptic glucose and glutamate transport and exacerbates ischemic brain injury. J Cerebr Blood Flow Metab. 2000;20:463&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">10724110</ArticleId></ArticleIdList></Reference><Reference><Citation>Katz JS, Rothstein JD, Cudkowicz ME, et al. . A phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS. Ann Clin Transl Neurol. 2022;9:50&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791798</ArticleId><ArticleId IdType="pubmed">35014217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>